AUTL — Autolus Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $428.49m
- $320.42m
- $10.12m
- 16
- 22
- 64
- 23
Annual income statement for Autolus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.72 | 2.33 | 6.36 | 1.7 | 10.1 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | -0.645 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 170 | 143 | 150 | 181 | 252 |
| Operating Profit | -168 | -141 | -143 | -180 | -241 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -166 | -142 | -149 | -208 | -219 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -142 | -142 | -149 | -208 | -221 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -142 | -142 | -149 | -208 | -221 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -142 | -142 | -149 | -208 | -221 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.74 | -1.97 | -1.56 | -1.18 | -0.863 |